Celltrion merger
Scope
Date
~
-
Bio & Pharma
Celltrion to supply Remsima, Herzuma to Peru
South Korea's Celltrion Inc. announced on Thursday that it secured a contract to supply its biosimilars for autoimmune disease treatment and antican...
May 02, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion releases Remsima SC in Denmark
South Korea's Celltrion Inc. announced on Thursday that it released its autoimmune disease treatment Remsima SC (infliximab) in Denmark. Remsima SC ...
Apr 19, 2024 (Gmt+09:00)
-
Bio & Pharma
Korea’s Celltrion, SK Biopharmaceuticals benefit from direct US sales
Celltrion Inc. and SK Biopharmaceuticals Co. are witnessing improving sales revenue and profitability by selling their products through their own ma...
Apr 16, 2024 (Gmt+09:00)
-
Mergers & Acquisitions
Hanmi’s planned merger with OCI scrapped as sons win family feud
Hanmi Pharmaceutical Group’s proposed merger with OCI Holdings Co. has collapsed after two sons of the group’s founding family, who oppo...
Mar 28, 2024 (Gmt+09:00)
-
Entertainment
K Enter moves step closer to Nasdaq listing in May
K Enter Holdings Inc., an umbrella entity of South Korea-based entertainment companies creating original entertainment content and managing related ...
Mar 27, 2024 (Gmt+09:00)
-
Corporate governance
Hanmi Science-OCI merger may gain traction with NPS' support
The merger of South Korea’s pharmaceutical holding firm Hanmi Science Co. and chemicals giant OCI Holdings Co. is likely to gain momentum as N...
Mar 27, 2024 (Gmt+09:00)
-
Mergers & Acquisitions
Proxy advisor KCGS backs Hanmi founder's sons return to board
South Korea’s top proxy advisory firm has recommended that shareholders of Hanmi Science Co. vote in favor of Hanmi Pharmaceutical Group&rsquo...
Mar 20, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion'a autoimmune disease drug Zymfentra makes US debut
South Korean biopharmaceutical giant Celltrion Inc. said on March 17 that it has launched its new autoimmune disease treatment Zymfentra in the US m...
Mar 18, 2024 (Gmt+09:00)
-
Korean chipmakers
SK Hynix explores HBM chip collaboration with Kioxia
SK Hynix Inc. is exploring collaboration with Japanese chipmaker Kioxia Holdings Corp. to produce high bandwidth memory (HBM) chips, which have been...
Mar 04, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion ships initial supply of Zymfentra to US
South Korea's Celltrion Inc. announced on Wednesday that it shipped the first supply of its subcutaneous injection type of the autoimmune disease tr...
Feb 29, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to deliver three treatments to Peru
South Korea’s Celltrion Inc. announced on Thursday that it will supply three treatments, including its blood cancer drug Truxima (rituximab) t...
Feb 15, 2024 (Gmt+09:00)
-
Airlines
T’way, Air Premia to take off with Korean Air-Asiana merger
The proposed 1.8 trillion-won ($1.3 billion) merger between Korean Air Lines Co. and Asiana Airlines Inc. will offer a tailwind to South Korea&rsquo...
Feb 14, 2024 (Gmt+09:00)
-
Mergers & Acquisitions
OCI-Hanmi merger faces tougher hurdles amid family feud
Hanmi Pharmaceutical Group’s aim to merge with chemicals giant OCI Group is hitting some roadblocks amid a prolonged feud between the family o...
Feb 13, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to supply Remsima SC, Yuflyma to Norway
South Korea's Celltrion Inc. announced on Wednesday that it will supply its autoimmune disease treatments Remsima SC (infliximab) and Yuflyma, the...
Feb 07, 2024 (Gmt+09:00)
-
Leadership & Management
Samsung’s Lee cleared of charges over Samsung C&T merger
The Seoul Central District Court on Monday acquitted Samsung Electronics Co. Chairman Jay Y. Lee of charges of being involved in illegal activities ...
Feb 05, 2024 (Gmt+09:00)
-
Airlines
Japan approves Korean Air-Asiana merger
Japan has finally given the nod to the merger between South Korea’s No. 1 full-service carrier Korean Air Lines Co. and No. 2 Asiana Airlines ...
Jan 31, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion, WuXi XDC to develop new antibody-drug conjugates
South Korea’s Celltrion Inc. has signed a business agreement with China’s WuXi XDC to jointly develop new antibody-drug conjugates (ADC)...
Jan 24, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to export three anticancer drugs to Europe
South Korea’s Celltrion Inc. announced on Thursday that it has secured supply contracts for three anticancer biosimilars in European countries...
Jan 18, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion Holdings eyes Nasdaq IPO by early 2025: chairman
South Korean biosimilar giant Celltrion Group is planning to debut on the Nasdaq market by early 2025, founder and Chairman Seo Jung-jin said at the...
Jan 16, 2024 (Gmt+09:00)
-
Mergers & Acquisitions
OCI-Hanmi merger to create Korea’s Bayer: OCI Chairman
Merging into one team, OCI Group and Hanmi Pharmaceutical Group will leap forward to be a global novel drug manufacturing and biotechnology innova...
Jan 15, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to expand Yuflyma supply network in Europe
South Korea’s Celltrion Inc. announced on Friday that it will supply its biosimilar Yuflyma (active ingredient: adalimumab) for the treatment ...
Jan 12, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion revises up earnings goals to overtake Amgen
Celltrion Inc., South Korea's leading biosimilar maker, on Wednesday expressed its ambition to join the global top 10 biotech and pharmaceutical com...
Jan 11, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for interchangeability of Yuflyma in US
South Korea's Celltrion Inc. announced on Wednesday that it has applied to the US Food and Drug Administration (FDA) for a modified approval to repl...
Jan 10, 2024 (Gmt+09:00)
-
Mergers & Acquisitions
Celltrion to sell portfolio of Takeda drugs to CBC Group
South Korea’s Celltrion Inc. will divest of a portfolio of Takeda Pharmaceutical's prescription medicines sold in Asia to CBC Group, a Singapo...
Jan 01, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for approval of Xolair biosimilar in Canada
South Korean biopharmaceutical company Celltrion Inc. announced on Wednesday that it has applied for CT-P39, a biosimilar of the treatment of asth...
Dec 27, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion’s Vegzelma listed on US PBM preferred drug list
South Korea's Celltrion Healthcare Co. announced on Tuesday that its anti-cancer biosimilar Vegzelma (active ingredient: bevacizumab) was listed as ...
Dec 12, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare's Herzuma selected as funded brand in NZ
Celltrion Healthcare Co. announced on Thursday that its biosimilar anticancer drug Herzuma (active ingredient trastuzumab) for breast and gastr...
Dec 07, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion, Cyron to develop multi-specific antibody new drug
South Korea’s biopharmaceutical company Celltrion Inc. announced on Wednesday that it signed a joint research agreement with domestic startup ...
Dec 06, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare's Remsima SC to be launched in US in 2024
Celltrion Healthcare Co. announced on Thursday that its autoimmune disease treatment Zymfentra (the US product name for Remsima SC) is set to be lau...
Nov 30, 2023 (Gmt+09:00)
-
Entertainment
CJ ENM, SK Square to merge OTTs to take on Netflix
CJ ENM Co., South Korea’s entertainment powerhouse, and SK Square Co., an investment unit of the country’s No. 2 conglomerate SK Group, ...
Nov 29, 2023 (Gmt+09:00)